ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+34.31%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$8.57B
AUM Growth
+$8.57B
(+18%)
Cap. Flow
+$830M
Cap. Flow
% of AUM
9.68%
Top 10 Holdings %
Top 10 Hldgs %
58.85%
Holding
53
New
11
Increased
15
Reduced
3
Closed
7
Top Buys
| 1 |
Viking Therapeutics
VKTX
|
$294M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$229M |
| 3 |
Vera Therapeutics
VERA
|
$227M |
| 4 |
Arrowhead Research
ARWR
|
$212M |
| 5 |
MacroGenics
MGNX
|
$90.5M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$287M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$262M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$121M |
| 4 |
Structure Therapeutics
GPCR
|
$95.1M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$39.6M |
Sector Composition
| 1 | Healthcare | 94.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Spyre Therapeutics
SYRE
$996M
| $69.8M | 0.81% | 1,839,138 | – | – |
|
27
Soleno Therapeutics
SLNO
$3.6B
| $69.6M | 0.81% | 1,625,000 +840,000 | +107% | +$36M |
|
28
BioCryst Pharmaceuticals
BCRX
$1.74B
| $66.3M | 0.77% | 13,050,000 | – | – |
|
29
Ocular Therapeutix
OCUL
$2.12B
| $65.1M | 0.76% | +7,148,936 | New | +$65.1M |
|
30
Taysha Gene Therapies
TSHA
$797M
| $53.5M | 0.62% | 18,650,000 +14,294,445 | +328% | +$41M |
|
31
Tourmaline Bio
TRML
$601M
| $50.9M | 0.59% | 2,222,222 +1,353,815 | +156% | +$31M |
|
32
Roivant Sciences
ROIV
$8.15B
| $49M | 0.57% | 4,651,162 | – | – |
|
|
33
Alnylam Pharmaceuticals
ALNY
$58.5B
| $44.8M | 0.52% | 300,000 -811,111 | -73% | -$121M |
|
34
MannKind Corp
MNKD
$1.41B
| $40.8M | 0.48% | 9,000,000 | – | – |
|
35
Merus
MRUS
$4.98B
| $40M | 0.47% | 888,888 | – | – |
|
36
Vaxcyte
PCVX
$4B
| $39.3M | 0.46% | +575,000 | New | +$39.3M |
|
37
Ultragenyx Pharmaceutical
RARE
$2.89B
| $38.8M | 0.45% | 830,000 +480,000 | +137% | +$22.4M |
|
|
MRNS
38
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $37.4M | 0.44% | 4,140,607 +990,607 | +31% | +$8.96M |
|
39
Rocket Pharmaceuticals
RCKT
$354M
| $34M | 0.4% | 1,260,900 | – | – |
|
40
Monte Rosa Therapeutics
GLUE
$296M
| $32M | 0.37% | 4,535,000 | – | – |
|
41
CG Oncology
CGON
$2.04B
| $30.7M | 0.36% | +700,000 | New | +$30.7M |
|
42
CRISPR Therapeutics
CRSP
$4.71B
| $28.6M | 0.33% | +419,580 | New | +$28.6M |
|
43
Verrica Pharmaceuticals
VRCA
$52.8M
| $23.7M | 0.28% | 3,999,999 | – | – |
|
44
Kyverna Therapeutics
KYTX
$160M
| $11.8M | 0.14% | +475,000 | New | +$11.8M |
|
|
WHWK
45
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.1M
| $6.67M | 0.08% | 2,849,402 | – | – |
|
46
Adverum Biotechnologies
ADVM
$64.6M
| $5.89M | 0.07% | +416,666 | New | +$5.89M |
|
47
Fennec Pharmaceuticals
FENC
$247M
| – | – | -1,200,000 | Closed | -$13.5M |
|
|
48
Structure Therapeutics
GPCR
$1.11B
| – | – | -2,333,333 | Closed | -$95.1M |
|
49
Nuvalent
NUVL
$5.52B
| – | – | -178,921 | Closed | -$13.2M |
|
|
CBAY
50
DELISTED
Cymabay Therapeutics
CBAY
| – | – | -11,111,111 | Closed | -$262M |
|